4 February 2021 - Theratechnologies is pleased to announce that the United States FDA has granted fast track designation to TH1902 as a single agent for the treatment of patients with sortilin positive recurrent advanced solid tumours that are refractory to standard therapy.
TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. This peptide-drug conjugate is the lead candidate stemming from Theratechnologies’ SORT1+ Technology™ in oncology.